DaVita Inc. (DVA) Price History:51.96%(TTM)
Over the latest trailing 12-month period, DaVita Inc. (DVA)'s price cagr is +51.96%. The comparable SPY value is +22.87%. Year-to-date price return is +82.22%. Price CAGR uses adjusted close price history and excludes dividends.
Current Price
$208.66
+$4.83 (+2.37%)
Previous Close: $203.83
Last Session
- Open
- $204.81
- Day High
- $211.80
- Day Low
- $204.06
- Volume
- 936.60K
- Avg Volume
- 843.90K
52-Week Position
97%
of the 52-week price range
- From 52-week high
- -1.48%
- From 52-week low
- +106.59%
52-Week Price Range
52-Week Low
$101.00
Jan 14, 2026
Current Price
$208.66
97% of range
52-Week High
$211.80
Jun 12, 2026
Price Returns by Period
1 Day
+2.37%
7 Days
+8.63%
30 Days
+4.47%
YTD
+82.22%
1 Year
+53.29%
vs 52W High
-1.48%
DVA Price Chart
Long-Term Performance (CAGR)
Price CAGR (3Y)
+29.04%
Price CAGR (5Y)
+11.28%
Total Return CAGR (3Y)
+29.04%
Total Return CAGR (5Y)
+11.28%
CAGR (Compound Annual Growth Rate) shows the annualized return over the specified period. Total Return includes dividends reinvested.
Key Price Statistics
| Current Price | $208.66 |
| Previous Close | $203.83 |
| Day Range | $204.06 - $211.80 |
| 52-Week Range | $101.00 - $211.80 |
| Volume | 936.60K |
| Average Volume | 843.90K |
| Market Cap | $13.40B |
| % from 52W High | -1.48% |
Related Metrics
About DaVita Inc.
DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- CEO
- Javier J. Rodriguez